Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University College Hospital Galway
With
Health Research Board, Ireland
National University of Ireland, Galway, Ireland
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 40 years or older
MDRD eGFR of 30-60ml/min/1.73m2 on ≥2 occasions ≥3 months apart
Most recent eGFR measurement within 3 months Systolic blood pressure \<160mmHg and diastolic blood pressure \<95mmHg on three office blood pressure readings at time of screening and confirmed by a study ABPM before randomisation of \<150/90mmHg
No change in anti-hypertensive or diuretic medications (including dose) for 3 months before screening visit
Consumption of moderate sodium intake at screening, defined as an estimated daily sodium intake of \>2.3g/day estimated from food frequency questionnaire (FFQ) completed during the screening visit
Self-reported willingness to modify dietary intake over sustained period, and adhere to directed recommendations over 2 years
Signed written informed consent
You may not be if
Acute Kidney Injury in the preceding three months, defined as doubling of baseline serum creatinine or rapidly declining eGFR over the preceding six months, defined as a decline in eGFR of ≥10ml/min/1.73m2 in those with established CKD
Any of the following renal conditions: glomerular disease due to post-infectious glomerulonephritis, IgA nephropathy, thin basement membrane disease, Henoch-Schonlein purpura, proliferative glomerulonephritis, membranous nephropathy (including lupus nephritis), rapidly progressive glomerulonephritis, minimal change disease, or focal segmental glomerulosclerosis
Prior or planned renal transplantation
Prior, current or planned renal dialysis
Medical diagnosis known to be associated with abnormal renal sodium excretion, including Bartter syndrome, SIADH, diabetes insipidus, or serum sodium \<125mmol
Severe heart failure (defined as left ventricular ejection fraction ≤30% or NYHA Class III/IV symptoms)
High-dose loop or thiazide diuretic therapy, exceeding a total daily dose of frusemide 80mg, bumetanide 2mg, hydrochlorothiazide 50mg, bendroflumethiazide 2.5mg, indapamide 2.5mg, metolazone 2.5mg or the use of both a loop and thiazide diuretic
Current use of non-steroidal anti-inflammatory drugs (NSAIDs) for 3 or more days per week. Low-dose aspirin \<100mg/day is not an exclusion
Unable to follow educational advice of the research team
Prescribed high-salt diet, low-salt diet or sodium bicarbonate
Symptomatic postural hypotension or receiving treatment for postural hypotension
Current or recent use (within one month) of immunosuppressive medications including tacrolimus, cyclosporine, azathioprine or mycophenolate mofetil
Pregnancy or lactation
Unable to comply with 24-hour urinary collections, or medical condition making collection of 24-hour urinary collection difficult (e.g. severe urinary incontinence)
Participant unlikely to comply with study procedures or follow-up visits due to severe co-morbid illness or other factor (e.g. inability to travel for follow-up visits, drug or alcohol misuse) in opinion of research team
Cognitive impairment defined as a known diagnosis of dementia, or inability to provide informed consent due to cognitive impairment in the opinion of the investigator
Body Mass Index (BMI) \<20kg/m2 or BMI\>40kg/m2
Participating in another clinical trial or previous allocation in this study
Clareo Health | Sodium Intake in Chronic Kidney Disease (STICK)
